Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells

Hormone Molecular Biology and Clinical Investigation

Volumn 3, Issue 2, 2010, Pages 417-424

  Chetrite, Gérard S ^a,b   Pasqualini, Jorge R ^a  

^a Hormones and Cancer Research Unit   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

anti aromatase; breast cancer; nomegestrol acetate; progestogen

Indexed keywords

ANDROSTENEDIONE; AROMATASE; DNA; ESTRADIOL; ESTRONE; NOMEGESTROL ACETATE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIMIT OF QUANTITATION; MCF 7ARO CELL LINE; MCF CELL LINE; PRIORITY JOURNAL; STANDARD; THIN LAYER CHROMATOGRAPHY;

EID: 84989190551     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.054     Document Type: Article

References (62)

1. Henderson BE., Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
2. Segaloff A. Hormones and mammary carcinogenesis. In: McGuire WL., editor. Breast cancer 2: advances in research and treatment; experimental biology. New York: Plenum Press., 1978:1-22.
3. Yager JD., Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
4. Chetrite GS., Cortes-Prieto J., Philippe JC., Wright F., Pasqualini JR. Comparison of estrogen concentrations., estrone sulfatase and aromatase activities in normal., and in cancerous., human breast tissues. J Steroid Biochem Mol Biol 2000;72:23-7.
5. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita HB., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils CH., Gonzalez CA., Gurrea AB., Critselis E., Khaw KT., Krogh V., Lahmann PH., Nagel G., Olsen A., Onland-Moret NC., Overvad K., Palli D., Panico S., Peeters P., Quiros JR., Roddam A., Thiebaut A., Tjonneland A., Chirlaque MD., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
6. Pasqualini JR., Chetrite GS., Nguyen B-L., Blacker C., Feinstein MC., Maloche C., Talbi M., Delalonde L. Control of estrone sul-fatase activity and its expression in human breast cancer. In: Motta M., Serio M., editors. Sex hormones and antihormones in endocrine dependent pathology: basic and clinical aspects. Amsterdam: Elsevier Science B.V., 1994:257-65.
7. Pasqualini JR., Chetrite G., Blacker C., Feinstein MC., Delalonde L., Talbi M., Maloche C. Concentrations of estrone., estradiol., and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-4.
8. Reed MJ., Cheng RW., Noel CT., Dudley HA., James VH. Plasma levels of estrone., estrone sulfate., and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res 1983;43:3940-3.
9. van Landeghem AA., Poortman J., Nabuurs M., Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6.
10. Vermeulen A., Deslypere JP., Paridaens R., Leclercq G., Roy F., Heuson JC. Aromatase., 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986;22:515-25.
11. Pasqualini JR., Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005;93: 221-36.
12. Pasqualini JR., Chetrite GS. The enzymatic systems in the formation and transformation of estrogens in normal and cancerous human breast: control and potential clinical applications. In: Pasqualini JR., editor. Breast cancer: prognosis., treatment and prevention., 2nd ed. New York: Informa Healthcare., 2008:11-48.
13. Brodie AM. Aromatase inhibitors and their application to the treatment of breast cancer. In: Pasqualini JR., editor. Breast cancer: prognosis., treatment and prevention. New York: Marcel Dekker Inc., 2002:251-69.
14. Brodie AM., Pasqualini JR., editors. Proceeding of the VIII International Aromatase Conference “AROMATASE 2006” Philadelphia. J Steroid Biochem Mol Biol 2007;106:1-186.
15. Miller W., Pasqualini JR., editors. Proceeding of the VII International Aromatase Conference “AROMATASE 2004” Edinburgh., Scotland., UK. J Steroid Biochem Mol Biol 2005;95: 1-188.
16. Sun XZ., Zhou D., Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 1997;63:29-36.
17. Lello S. Nomegestrol acetate: pharmacology., safety profile and therapeutic efficacy. Drugs 2010;70:541-59.
18. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1956;62:315-23.
19. Chetrite G., Paris J., Botella J., Pasqualini JR. Effect of nome-gestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996;58:525-31.
20. Pasqualini JR., Chetrite G., Nguyen BL., Maloche C., Delalonde L., Talbi M., Feinstein MC., Blacker C., Botella J., Paris J. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 1995;53:407-12.
21. Labrie F., Belanger A., Luu-The V., Labrie C., Simard J., Cusan L., Gomez JL., Candas B. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 1998;63:322-8.
22. Lamar CA., Dorgan JF., Longcope C., Stanczyk FZ., Falk RT., Stephenson HE Jr. Serum sex hormones and breast cancer risk factors in postmenopausal women. Cancer Epidemiol Biomar-kers Prev 2003;12:380-3.
23. Szymczak J., Milewicz A., Thijssen JH., Blankenstein MA., Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;63:319-21.
24. Thijssen JH., van Landeghem AA., Poortman J. Uptake and concentration of steroid hormones in mammary tissues. Ann N Y Acad Sci 1986;464:106-16.
25. Hankinson SE., Willett WC., Manson JE., Colditz GA., Hunter DJ., Spiegelman D., Barbieri RL., Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
26. James VH., Reed MJ., Beranek PA., Bonney RC., Samuel DL., Newton CJ., Franks S., Ghilchik MW. Androgen and estrogen metabolism in breast cancer patients. Ann N Y Acad Sci 1986; 464:117-25.
27. Suzuki T., Nakata T., Miki Y., Kaneko C., Moriya T., Ishida T., Akinaga S., Hirakawa H., Kimura M., Sasano H. Estrogen sul-fotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 2003;63:2762-70.
28. Yue W., Berstein LM., Wang JP., Clark GM., Hamilton CJ., Demers LM., Santen RJ. The potential role of estrogen in aromatase regulation in the breast. J Steroid Biochem Mol Biol 2001;79: 157-64.
29. Key TJ., Appleby PN., Reeves GK., Roddam A., Dorgan JF., Long-cope C., Stanczyk FZ., Stephenson HE Jr., Falk RT., Miller R., Schatzkin A., Allen DS., Fentiman IS., Wang DY., Dowsett M., Thomas HV., Hankinson SE., Toniolo P., Akhmedkhanov A., Koe-nig K., Shore RE., Zeleniuch-Jacquotte A., Berrino F., Muti P., Micheli A., Krogh V., Sieri S., Pala V., Venturelli E., Secreto G., Barrett-Connor E., Laughlin GA., Kabuto M., Akiba S., Stevens RG., Neriishi K., Land CE., Cauley JA., Kuller LH., Cummings SR., Helzlsouer KJ., Alberg AJ., Bush TL., Comstock GW., Gordon GB., Miller SR. Body mass index., serum sex hormones., and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
30. Brodie AM. Aromatase inhibitors and their application to the treatment of breast cancer. In: Pasqualini JR., editor. Breast cancer: prognosis., treatment and prevention., 2nd ed. New York: Informa Healthcare., 2008:157-68.
31. Miller WR. Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast. Endocr Relat Cancer 1999;6: 187-95.
32. Smith IE., Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
33. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
34. Eden J. Progestins and breast cancer. Am J Obstet Gynecol 2003;188:1123-31.
35. Rossouw JE., Anderson GL., Prentice RL., LaCroix AZ., Kooper-berg C., Stefanick ML., Jackson RD., Beresford SA., Howard BV., Johnson KC., Kotchen JM., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
36. Ross RK., Paganini-Hill A., Wan PC., Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
37. Shields-Botella J., Duc I., Duranti E., Puccio F., Bonnet P., Delan-sorne R., Paris J. An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells. J Steroid Biochem Mol Biol 2003;87: 111-22.
38. Botella J., Duranti E., Duc I., Cognet AM., Delansorne R., Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994; 50:41-7.
39. Botella J., Duranti E., Viader V., Duc I., Delansorne R., Paris J. Lack of estrogenic potential of progesterone-or 19-nor-proges-terone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells. J Steroid Biochem Mol Biol 1995;55:77-84.
40. Catherino WH., Jordan VC. Nomegestrol acetate., a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-46.
41. Duc I., Botella J., Bonnet P., Fraboul F., Delansorne R., Paris J. Antiandrogenic properties of nomegestrol acetate. Arzneimittel-forschung 1995;45:70-4.
42. Williams JK., Cline JM., Honore EK., Delansorne R., Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998;179:1288-94.
43. Zerr-Fouineau M., Jourdain M., Boesch C., Hecker M., Bronner C., Schini-Kerth VB. Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:586-93.
44. Simoncini T., Caruso A., Garibaldi S., Fu XD., Giretti MS., Bal-dacci C., Scorticati C., Fornari L., Mannella P., Genazzani AR. Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate. Obstet Gynecol 2006;108:969-78.
45. Li J., Xu LZ., He KL., Guo WJ., Zheng YH., Xia P., Chen Y. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001;3:253-63.
46. Chetrite GS., Thomas JL., Shields-Botella J., Cortes-Prieto J., Philippe JC., Pasqualini JR. Control of sulfatase activity by nome-gestrol acetate in normal and cancerous human breast tissues. Anticancer Res 2005;25:2827-30.
47. Chetrite GS., Paris J., Shields-Botella J., Philippe JC., Pasqualini JR. Effect of nomegestrol acetate on human estrogen sulfotrans-ferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines. Anticancer Res 2003;23:4651-5.
48. Pasqualini JR., Chetrite GS. Correlation of estrogen sulfotrans-ferase activity and proliferation in normal and carcinomatous human breast. A hypothesis. Anticancer Res 2007;27:3219-25.
49. Covey DF., Hood WF., McMullan PC. Studies of the inactivation of human placental aromatase by 17 alpha-ethynyl-substituted 10 beta-hydroperoxy and related 19-nor steroids. Biochem Pharmacol 1986;35:1671-4.
50. Killinger DW., Perel E., Daniilescu D., Kharlip L., Blackstein ME. Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation. Steroids 1987;50:523-36.
51. Pasqualini JR., Chetrite G. The anti-aromatase effect of progesterone and of its natural metabolites 20alpha-and 5alpha-dihy-droprogesterone in the MCF-7aro breast cancer cell line. Anticancer Res 2008;28:2129-33.
52. Purohit A., Lai LC., Singh A., Coldham NG., Ghilchik MW., Reed MJ., James VH. The effect of medroxyprogesterone acetate on aromatase and DNA polymerase alpha activities in breast tumours. J Steroid Biochem 1989;34:443-6.
53. Satoh T., Itoh S., Seki T., Nomura N., Yoshizawa I. On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production. J Steroid Biochem Mol Biol 2002;82: 209-16.
54. Perel E., Daniilescu D., Kharlip L., Blackstein M., Killinger DW. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J Steroid Biochem 1988;29:393-9.
55. Ezan E., Benech H., Bucourt R., Ardouin T., Tchernatinsky C., Thomas JL., Paris J., Grognet JM. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-14.
56. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-83.
57. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215.
58. Chetrite GS., Cortes-Prieto JC., Philippe JC., Pasqualini JR. Estra-diol inhibits the estrone sulfatase activity in normal and cancerous human breast tissues. J Steroid Biochem Mol Biol 2007; 104:289-92.
59. Pasqualini JR., Chetrite G. Paradoxical effect of estradiol: it can block its own bioformation in human breast cancer cells. J Steroid Biochem Mol Biol 2001;78:21-4.
60. Pasqualini JR., Chetrite GS. Estradiol as an anti-aromatase agent in human breast cancer cells. J Steroid Biochem Mol Biol 2006;98:12-7.
61. Chetrite GS., Pasqualini JR. Inhibition of aromatase activity in MCF-7aro human breast cancer cells by the natural androgens testosterone and androstenedione. Horm Mol Biol Clin Invest 2010;1:147-53.
62. Wiebe JP., Muzia D., Hu J., Szwajcer D., Hill SA., Seachrist JL. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000;60:936-43.